Critical tumor-suppressor gene regions on chromosome 3p in major human epithelial malignancies: Allelotyping and quantitative real-time PCR

被引:55
作者
Braga, E
Senchenko, V
Bazov, I
Loginov, W
Liu, J
Ermilova, V
Kazubskaya, T
Garkavtseva, R
Mazurenko, N
Kisseljov, F
Lerman, MI
Klein, G
Kisselev, L
Zabarovsky, ER
机构
[1] Karolinska Inst, MTC, Ctr Genom Res, Microbiol & Tumor Biol Ctr, S-17177 Stockholm, Sweden
[2] Russian State Genet Ctr, Moscow, Russia
[3] Russian Acad Sci, Ctr Bioengn, Moscow, Russia
[4] Russian Acad Med Sci, Blokhir Canc Res Ctr, Moscow, Russia
[5] NCI, Immunobiol Lab, Frederick, MD 21701 USA
[6] Russian Acad Sci, VA Engelhardt Mol Biol Inst, Moscow, Russia
关键词
chromosome; 3p; tumor-suppressor gene; loss of heterozygosity; allelotyping; renal cell carcinoma;
D O I
10.1002/ijc.10511
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
To ascertain the involvement of human chromosome 3p and its established critical TSG regions in various epithelial malignancies, 21 polymorphic and 2 nonpolymorphic 3p markers were allelotyped in nonpapillary RCC, NSCLC, CC and BC from a total of 184 patients. LOH was observed with high frequency in all types of cancer studied: RCC (52/57, 91%), BC (41/51, 80%), NSCLC (30/40, 75%) and CC (27/36, 75%). Interstitial deletions, believed to signal TSG inactivation, were verified using the "L-allele rule" and real-time quantitative PCR. Significant correlation was observed between DNA copy numbers for 2 nonpolymorphic STS markers and LOH data for adjacent polymorphic loci. Interstitial deletions in 3p were demonstrated for all cancer types studied. However, the distribution of different types of deletion was characteristic for tumors from various locations. Large terminal deletions were predominantly seen in RCC and NSCLC (51% and 40%, respectively), correlating with clear cell RCC and squamous cell carcinomas of the lung. In addition to the LUCA region at 3p21.3 (centromeric), we found that the AP20 region (3p21.3, telomeric) was frequently affected in all 4 cancers, suggesting that this newly defined critical region contains multiple TSGs. Moreover, at least 3 candidate cancer-specific loci were identified. The telomeric 3p26.1-p2S.3 region was predominantly deleted in RCC and NSCLC. The D3S1286 and D3S3047 markers (3p25.2-p24.3) were deleted nonrandomly in NSCLC. High-frequency LOH was detected in a segment mapped closely distal to the LUCA site (3p21.3), around the D3S2409 and D3S2456 markers. (C) 2002 Wiley-Liss, Inc.
引用
收藏
页码:534 / 541
页数:8
相关论文
共 61 条
[1]   Combined LOH/CGH analysis proves the existence of interstitial 3p deletions in renal cell carcinoma [J].
Alimov, A ;
Kost-Alimova, M ;
Liu, J ;
Li, CD ;
Bergerheim, U ;
Imreh, S ;
Klein, G ;
Zabarovsky, ER .
ONCOGENE, 2000, 19 (11) :1392-1399
[2]  
[Anonymous], 1990, GENETIC DATA ANAL
[3]   Gene dosage by quantitative real-time PCR [J].
Boulay, JL ;
Reuter, J ;
Ritschard, R ;
Terracciano, L ;
Herrmann, R ;
Rochlitz, C .
BIOTECHNIQUES, 1999, 27 (02) :228-+
[4]   Comparative allelotyping of the short arm of human chromosome 3 in epithelial tumors of four different types [J].
Braga, E ;
Pugacheva, E ;
Bazov, I ;
Ermilova, V ;
Kazubskaya, T ;
Mazurenko, N ;
Kisseljov, F ;
Liu, J ;
Garkavtseva, R ;
Zabarovsky, E ;
Kisselev, L .
FEBS LETTERS, 1999, 454 (03) :215-219
[5]  
Braga E. A., 1997, Molekulyarnaya Biologiya (Moscow), V31, P985
[6]   Epigenetic inactivation of RASSF14 in lung and breast cancers and malignant phenotype suppression [J].
Burbee, DG ;
Forgacs, E ;
Zöchbauer-Müller, S ;
Shivakumar, L ;
Fong, K ;
Gao, BN ;
Randle, D ;
Kondo, M ;
Virmani, A ;
Bader, S ;
Sekido, Y ;
Latif, F ;
Milchgrub, S ;
Toyooka, S ;
Gazdar, AF ;
Lerman, MI ;
Zabarovsky, E ;
White, M ;
Minna, JD .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2001, 93 (09) :691-699
[7]   Functional evidence for a nasopharyngeal carcinoma tumor suppressor gene that maps at chromosome 3p21.3 [J].
Cheng, Y ;
Poulos, NE ;
Lung, ML ;
Hampton, G ;
Ou, BX ;
Lerman, MI ;
Stanbridge, EJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (06) :3042-3047
[8]  
Chudek J, 1997, INT J CANCER, V73, P225, DOI 10.1002/(SICI)1097-0215(19971009)73:2<225::AID-IJC11>3.0.CO
[9]  
2-E
[10]  
Clifford SC, 1998, GENE CHROMOSOME CANC, V22, P200, DOI 10.1002/(SICI)1098-2264(199807)22:3<200::AID-GCC5>3.0.CO